THUMPD3-AS1 Is Correlated with Gastric Cancer and Regulates Cell Function through miR-1252-3p and CXCL17.
Crit Rev Eukaryot Gene Expr
; 32(8): 69-80, 2022.
Article
em En
| MEDLINE
| ID: mdl-36017917
ABSTRACT
The problem facing gastric cancer treatment is the uncontrollable prognosis. Long noncoding RNAs (lncRNAs) are the current hotspot for gastric cancer prognostic markers. This study was targeted at determining THUMPD3-AS1 expression in gastric cancer, and then exploring whether THUMPD3-AS1 is associated with prognosis and its role in cancerous cell function. THUMPD3-AS1 expression levels were quantified in human tissues and cell lines. The prognostic biomarker potential of THUMPD3-AS1 was evaluated by Kaplan-Meier and multivariate Cox regression analyses. The biological impact of THUMPD3-AS1 in gastric cancer cells was investigated by WST-1, Tran-swell, and reactive oxygen species (ROS) accumulation assay. The binding between THUMPD3-AS1, miR-1252-3p and CXCL17 was verified by luciferase reporter assay and RNA pulled down assay. THUMPD3-AS1 was significantly decreased in gastric cancer tissues and cells by comparing them with normal ones. THUMPD3-AS1 was related to the advanced TNM stage, lymphatic infiltration, and vascular infiltration. Downregulated THUMPD3-AS1 was associated with reduced 5-year overall survival. Overexpression of THUMPD3-AS1 inhibits proliferation, migration, invasion and ROS accumulation of gastric cancer cells by regulation of miR-1252-3p and CXCL17. THUMPD3-AS1 could be a potent prognostic symbol for patients with gastric cancer. THUMPD3-AS1 provides a therapeutic potential for gastric cancer.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Gástricas
/
MicroRNAs
/
RNA Longo não Codificante
Limite:
Humans
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article